ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics Press release Key updates September 12, 2017
ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Press release … Inosine is translated as a Guanosine (G). A member of the Scientific Advisory Board, Dr. Levin will present the landscape and evolution of … June 15, 2017
ProQR Announces Results for the Third Quarter of 2017 Press release … ODD from FDA and pre-clinical data was presented at two scientific meetings. QR-313 is expected to enter the clinic … and Thaddeus (Ted) Dryja appointed to ProQR’s Scientific Advisory Board (SAB). In vivo proof of concept data for novel Axiomer … November 20, 2017
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results Press release LEIDEN, The Netherlands & CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 27, 2019
ProQR Announces Second Quarter 2020 Operating and Financial Results Press release … We are also pleased to have strengthened our Scientific Advisory Board with leading experts in IRD and RNA therapies who will … August 06, 2020
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results Press release … operationally on several fronts. We strengthened our Scientific Advisory Board with the addition of leading experts in IRDs and RNA … February 25, 2021
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update Press release Key updates February 28, 2018
ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference Press release LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 04, 2018
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 28, 2023